Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00884858 |
Recruitment Status
:
Completed
First Posted
: April 21, 2009
Last Update Posted
: April 30, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Suboptimal improvement in cluster of differentiation 4 (CD4) cell count is not uncommon in HIV-1-infected patients with suppressed plasma HIV-Ribonucleic acid (RNA) levels, and a decrease in CD4 cell count in patients with suppressed or low level viremia has been observed.
Although the efficacy of current antiretroviral medications is well established, some antiviral combinations are very effective in suppressing HIV-1 load whereas do not exert any effect on immune reconstitution.
Both T-cell immune activation and fibrosis of peripheral lymphoid tissue could create an environment in which CD4 T cell count decrease in the setting of low or suppressed plasma viremia is likely to occur.
Another fascinating hypothesis, which has still to be elucidated, is that reconstitution of the depleted CD4 pool is blocked by an excess of glycoprotein 120 (gp120) HIV-1 protein. This extra-production could be counteracted by an inhibitor of the chemokine (C-C motif) receptor 5 (CCR5) co-receptor that represents one of the major docking tools of HIV-1.
With this in mind, the investigators would like to propose and design a pilot exploratory clinical trial involving a population of HIV-1-infected patients that rapidly reached a virologic suppression without a reconstitution of their immune system.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Maraviroc | Phase 4 |
Objectives:
- Evaluate the clinical efficacy of HAART intensification with MVC as treatment of HIV-1 infection in patients with a CD4 count ≤ 200 cells/uL and/or a recovery of CD4 cells < 25% compared to the HAART initiation and with a complete and stable virologic suppression after 12 months of HAART. Patients could also being included if their CD4 slope has been stable without any improvement, with an absolute value around 200 cells/uL.
- Evaluate the effects of HAART intensification with MVC on the modification of immunologic and virologic parameters.
- Evaluate the tolerability of HAART intensification with MVC and the appearance of drug-related side effects.
Design:
This will be a randomised, multicenter, study that will evaluate HAART intensification with MVC as treatment of HIV-1 infection in patients with a CD4 count ≤ 200 cells/uL and/or a recovery of CD4 cells < 25% compared to the HAART initiation and/or a stable CD4 slope without any improvement, with an absolute value around 200 cells/uL and with a complete and stable virologic suppression after 12 months of HAART.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients. |
Study Start Date : | April 2009 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | April 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Maraviroc
Subjects in this group will add Maraviroc to their current HAART.
|
Drug: Maraviroc
Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
Other Name: Maraviroc brand name in the EC is Celsentri.
|
No Intervention: 2
Subjects in this group will continue their current HAART without adding Maraviroc.
|
- CD4 counts > 200/uL or recovery of CD4 > 25% in 2 consecutive time-points. [ Time Frame: 3 and 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age > or = 18
- HIV-Abs positivity detected by ELISA and confirmed by Western-Blot
- CD4 lymphocytes < 200/uL and/or CD4 recovery < 25% after at least 12 months of stable HAART
- HIV-RNA < 50 cp/mL during the last 12 months
- negative pregnancy test at least 14 days prior to treatment
- understanding and signing the informed consent
Exclusion Criteria:
- allergy/intolerance to the study drug
- less than 1 year from any treatment with immunomodulatory agents
- current OIs or neoplasms
- current CVD or EKG abnormalities
- current respiratory tract diseases or COPD
- treatment with steroids within 4 weeks from treatment beginning
- suspect of autoimmune disorder or chronic inflammatory disease
- active IVDUs or alcohol addicts
- AST and ALT > 2.5 ULD
- serum creatinine > 1.5 ULD
- ANC < 1000/uL
- hemoglobin < 10 g/dL
- platelets < 75.000/uL
- reticulocytes > 2%
- Karnofsky score < 50

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00884858
Italy | |
Servizio Regionale di Immunologia Clinica e Tipizzazione Tissutale, Azienda Ospedaliero-Universitaria | |
Torrette di Ancona, AN, Italy, 60126 | |
Clinica di Malattie Infettive, Policlinico, Universita' degli Studi | |
Bari, BA, Italy, 70124 | |
Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Spedali civili | |
Brescia, BS, Italy, 25125 | |
Divisione di Malattie Infettive, Ospedale S. Maria Annunziata | |
Antella, FI, Italy, 50011 | |
Clinica di Malattie Infettive, Ospedale San Martino | |
Genova, GE, Italy, 16132 | |
Divisione di Malattie Infettive, Ospedale San Gerardo | |
Monza, MB, Italy, 20052 | |
Polo di Medicina Chirurgia e Odontoiatria, Polo Didattico S. Paolo | |
Milano, MI, Italy, 20124 | |
U.O di Malattie Infettive, Fondazione San Raffaele del Monte Tabor | |
Milano, MI, Italy, 20132 | |
Divisione Clinicizzata di Malatie Infettive, Azienda Ospedaliera-Polo Universitario "Luigi Sacco" | |
Milano, MI, Italy, 20157 | |
I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario Luigi Sacco | |
Milano, MI, Italy, 20157 | |
Clinica delle Malattie Infettive, Policlinico Universitario | |
Modena, MO, Italy, 41100 | |
U.O. Malattie Infettive, Ospedale S. Spirito | |
Pescara, PE, Italy, 65100 | |
Clinica delle Malattie Infettive, Policlinico Monteluce | |
Perugia, PG, Italy, 06126 | |
Clinica delle Malattie Infettive, Policlinico "Tor Vergata" | |
Roma, RM, Italy, 00133 | |
III Divisione di Malattie Infettive, I.N.M.I Lazzaro Spallanzani | |
Roma, RM, Italy, 00149 | |
IV Divisione di Malattie Infettive, INMI Lazzaro Spallanzani | |
Roma, RM, Italy, 00149 | |
U.O. Malattie Infettive, Azienda Policlinico Umberto I | |
Roma, RM, Italy, 00161 | |
Istituto Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore | |
Roma, RM, Italy, 00168 | |
Clinica delle Malattie Infettive ,Ospedale Amedeo di Savoia | |
Torino, TO, Italy, 10149 | |
Divisione Dipartimento Urgenze Infettivologiche ad Alta Complessità e correlate all'AIDS, Ospedale Cotugno | |
Napoli, Italy, 80131 |
Principal Investigator: | Stefano Rusconi, M.D. | Universita' degli Studi di Milano, Italy |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Stefano Rusconi, Researcher/Aggregate professor in infectious diseases, Ospedale L. Sacco - Polo Universitario |
ClinicalTrials.gov Identifier: | NCT00884858 History of Changes |
Other Study ID Numbers: |
HLS/MVC01/2008 |
First Posted: | April 21, 2009 Key Record Dates |
Last Update Posted: | April 30, 2013 |
Last Verified: | April 2013 |
Keywords provided by Stefano Rusconi, Ospedale L. Sacco - Polo Universitario:
HIV-1 CD4 INR |
HIV-1 infection extreme immunological compromission treatment experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes |
Immune System Diseases Maraviroc CCR5 Receptor Antagonists Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |